Transcriptional profiling of circulating tumor cells: Quantification and cancer Progression (review)

Oncology Reports

Volumn 10, Issue 1, 2003, Pages 229-235

  Wong, Ivy H N ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Metastasis; Quantitative reverse transcription polymerase chain reaction; Transcription profile; Tumor recurrence

Indexed keywords

MESSENGER RNA; TUMOR MARKER;

DISEASE COURSE; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; GENETICS; HUMAN; MONITORING; NEOPLASM; PROGNOSIS; REVIEW; TUMOR EMBOLISM;

DISEASE PROGRESSION; GENE EXPRESSION PROFILING; HUMANS; MONITORING, PHYSIOLOGIC; NEOPLASM CIRCULATING CELLS; NEOPLASMS; PROGNOSIS; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TUMOR MARKERS, BIOLOGICAL;

EID: 0041777249     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.10.1.229     Document Type: Review

References (63)

1. Zetter BR: Angiogenesis and tumor metastasis. Annu Rev Med 49: 407-424, 1998.
2. Liotta LA and Kohn EC: The microenvironment of the tumour-host interface. Nature 411: 375-379, 2001.
3. Wilhelm MC, Edge SB, Cole DD, De Paredes E and Frierson HF Jr: Non-palpable invasive breast cancer. Ann Surg 213: 600-605, 1991.
4. Greenway B: Hepatic metastases from colorectal cancer: resection or not. Br J Surg 75: 513-519, 1988.
5. Lindemann F, Schlimok G, Dirschedi P, Witte J and Riethmuller G: Prognostic significance of micrometastatic tumor cells in bone marrow of colorectal cancer patients. Lancet 340: 685-689, 1992.
6. Cote RJ, Rosen PP, Lesser ML, Old LJ and Osborne MP: Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J Clin Oncol 9: 1749-1756, 1991.
7. Wadayama B, Toguchida J, Shimizu T, Ishizaki K, Sasaki MS, Kotoura Y and Yamamuro T: Mutation spectrum of the retinoblastoma gene in osteosarcomas. Cancer Res 54: 3042-3048, 1994. (Pubitemid 24187793)
8. McIntyre JF, Smith-Sorensen B, Friend SH, et al: Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma. J Clin Oncol 12: 925-930, 1994. (Pubitemid 24145318)
9. Ladanyi M, Cha C, Lewis R, Jhanwar SC, Huvos AG and Healey JH: MDM2 gene amplification in metastatic osteosarcoma. Cancer Res 53: 16-18, 1993. (Pubitemid 23019370)
10. Ladanyi M, Park CK, Lewis R, Jhanwar SC, Healey JH and Huvos AG: Sporadic amplification of the MYC gene in human osteosarcomas. Diagn Mol Pathol 2: 163-167, 1993. (Pubitemid 23252434)
11. Onda M, Matsuda S, Higaki S, et al: ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma. Cancer 77: 71-78, 1996. (Pubitemid 26002739)
12. Meyers PA, Heller G, Healey JH, Huvos A, Applewhite A, Sun M and La Quaglia M: Osteogenic sarcoma with clinically detectable metastasis at initial presentation. J Clin Oncol 11: 449-453, 1993. (Pubitemid 23071040)
13. Meyers PA and Gorlick R: Osteosarcoma. Pediatr Clin North Am 44: 973-989, 1997. (Pubitemid 27368674)
14. Wong IHN, Lau WY, Leung T, Yeo W and Johnson PJ: Hematogenous dissemination of hepatocytes and tumor cells after surgical resection of hepatocellular carcinoma: a quantitative analysis. Clin Cancer Res 5: 4021-4027, 1999. (Pubitemid 30013779)
15. Wong IHN, Ng MHL, Huang DP and Lee JCK: Aberrant p15 promoter methylation in adult and childhood acute leukemias of nearly all the morphologic subtypes: potential prognostic implications. Blood 95: 1942-1949, 2000. (Pubitemid 30151630)
16. Belghiti J, Panis Y, Farges O, Benhamou JP and Fekete F: Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. Ann Surg 214: 114-117, 1991.
17. Ghossein RA, Scher HI, Gerald WL, et al: Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implications. J Clin Oncol 13: 1195-1200, 1995.
18. Noguchi S, Aihara T, Motomura K, Inaji H, Imaoka S and Koyama H: Detection of breast cancer micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction. Comparison between MUC1 mRNA and keratin 19 mRNA amplification. Am J Pathol 148: 649-656, 1996. (Pubitemid 26056749)
19. Liefers G J, Cleton-Jansen AM, van de Velde CJ, Hermans J, van Krieken JH, Cornelisse CJ and Tollenaar RA: Micrometastases and survival in stage II colorectal cancer. N Engl J Med 339: 223-228, 1998. (Pubitemid 28350164)
20. Peck K, Sher YP, Shih JY, Roffler SR, Wu CW and Yang PC: Detection and quantitation of circulating cancer cells in the peripheral blood of lung cancer patients. Cancer Res 58: 2761-2765, 1998. (Pubitemid 28311905)
21. Ni H, Nitta M, Komatsu H, et al: Detection of bcr/abl fusion transcripts by semi-quantitative multiplex RT-PCR combined with a colormetric assay in Ph positive leukemia. Cancer Lett 124: 173-180, 1998. (Pubitemid 28073684)
22. Yuasa T, Yoshiki T, Tanaka T, Isono T and Okada Y: Detection of circulating testicular cancer cells in peripheral blood. Cancer Lett 143: 57-62, 1999. (Pubitemid 29327190)
23. Wong IHN, Chan AT and Johnson PJ: Quantitative analysis of circulating tumor cells in peripheral blood of osteosarcoma patients using osteoblast-specific mRNA markers: a pilot study. Clin Cancer Res 6: 2183-2188, 2000. (Pubitemid 30399183)
24. Eschwege P, Dumas F, Blanchet P, et al: Haematogenous dissemination of prostatic epithelial cells during radical prostatectomy. Lancet 346: 1528-1530, 1995.
25. Pantel K, Izbicki J, Passlick B, Angstwurm M, Haussinger K, Thetter O and Riethmuller G: Frequency and prognostic significance of isolated tumor cells in bone marrow of patients with non-small-cell lung cancer without overt metastases. Lancet 347: 649-653, 1996. (Pubitemid 26076131)
26. Wong IHN, Yeo W, Leung T, Lau WY and Johnson PJ: Circulating tumor cell mRNAs in peripheral blood from hepatocellular carcinoma patients under radiotherapy, surgical resection or chemotherapy: a quantitative evaluation. Cancer Lett 167: 183-191, 2001. (Pubitemid 32706682)
27. Wong IHN, Yeo W, Chan AT and Johnson PJ: Quantitative relationship of the circulating tumor burden assessed by RTPCR for cytokeratin 19 mRNA in peripheral blood of colorectal cancer patients with Duke's stage, serum carcinoembryonic antigen level and tumor progression. Cancer Lett 162: 65-73, 2001.
28. Wong IHN, Yeo W, Chan AT and Johnson PJ: Quantitative correlation of cytokeratin 19 mRNA in peripheral blood with disease stage and metastasis in breast cancer patients: potential prognostic implications. Int J Oncol 18: 633-638, 2001.
29. Wong IHN, Leung T, Ho S, Lau WY, Chan M and Johnson PJ: Semi-quantification of circulating hepatocellular carcinoma cells by reverse transcriptase polymerase chain reaction. Br J Cancer 76: 628-633, 1997. (Pubitemid 27354677)
30. Wong IHN, Yeo W, Leung T, Lau WY and Johnson PJ: Circulating comparison of alpha-fetoprotein and albumin mRNA levels in hepatocellular carcinoma/adenoma, non-tumor liver and blood: implications in cancer detection and monitoring. Cancer Lett 156: 141-149, 2000. (Pubitemid 30394671)
31. Wong IHN, Chan AT and Johnson PJ: Molecular analysis of circulating tumor cells in peripheral blood from patients with germ cell tumor: a quantitative approach. Int J Mol Med 6: 491-494, 2000.
32. Dingemans AM, Brakenhoff RH, Postmus PE and Giaccone G: Detection of cytokeratin-19 transcripts by reverse transcriptase polymerase chain reaction in lung cancer cell lines and blood of lung cancerpatients. Lab Invest 77: 213-220, 1997. (Pubitemid 27413534)
33. Jonas S, Windeatt S, Boateng A, Fordy C and Allen-Mersh TG: Identification of carcinoembryonic antigen-producing cells circulating in the blood of patients with colorectal carcinoma by reverse transcriptase polymerase chain reaction. Gut 39: 717-721, 1996. (Pubitemid 26426474)
34. Krismann M, Todt B, Schroder J, Gareis D, Muller KM, Seeber S and Schutte J: Low specificity of cytokeratin 19 reverse transcriptase-polymerase chain reaction analyzes for detection of hematogenous lung cancer dissemination. J Clin Oncol 13: 2769-2775, 1995.
35. Datta YH, Adams PT, Drobyski WR, Ethier SP, Terry VH and Roth MS: Sensitive detection of occult breast cancer by the reverse transcriptase polymerase chain reaction. J Clin Oncol 12: 475-482, 1994. (Pubitemid 24079887)
36. Grigoriadis AE, Schellander K, Wang ZQ and Wagner EF: Osteoblasts are target cells for transformation in c-fos transgenic mice. J Cell Biol 122: 685-701, 1993. (Pubitemid 23226685)
37. Matsumura M, Niwa Y, Kato N, et al: Detection of alpha-fetoprotein mRNA, an indicator of hematogenous spreading hepatocellular carcinoma, in the circulation: a possible predictor of metastatic hepatocellular carcinoma. Hepatology 20: 1418-1425, 1994. (Pubitemid 24359050)
38. Komeda T, Fukuda Y, Sando T, et al: Sensitive detection of circulating hepatocellular carcinoma cells in peripheral venous blood. Cancer 75: 2214-2219, 1995.
39. Funaki NO, Tanaka J, Seto SI, Kasamatsu T, Kaido T and Imamura M: Hematogenous spreading of hepatocellular carcinoma cells: possible participation in recurrence in the liver. Hepatology 25: 564-568, 1997. (Pubitemid 27106434)
40. Louha M, Poussin K, Ganne N, et al: Spontaneous and Iatrogenic spreading of liver-derived cells into peripheral blood of patients with primary liver cancer. Hepatology 26: 998-1005, 1997. (Pubitemid 27413670)
41. Hillaire S, Barbu V, Boucher E, Moukhtar M and Poupon R: Albumin messenger RNA as a marker of circulating hepatocytes in hepatocellular carcinoma. Gastroenterology 106: 239-242, 1994. (Pubitemid 24011887)
42. Kar S and Carr B: Detection of liver cells in peripheral blood of patients with advanced-stage hepatocellular carcinoma. Hepatology 21: 403-407, 1995.
43. Ohguchi S, Nakatsukasa H, Higashi T, et al: Expression of alpha-fetoprotein and albumin genes in human hepatocellular carcinomas: limitations in the application of the genes for targeting human hepatocellular carcinoma in gene therapy. Hepatology 27: 599-607, 1998. (Pubitemid 28081079)
44. Racila E, Euhus D, Weiss AJ, Rao C, McConnell J, Terstappen LW and Uhr JW: Detection and characterization of carcinoma cells in the blood. Proc Natl Acad Sci USA 95: 4589-4594, 1998. (Pubitemid 28207957)
45. Braun S, Pantel K, Müller P, et al: Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 342: 525-533, 2000. (Pubitemid 30117892)
46. Kawaguchi T and Nakamura K: Analysis of the lodgment and extravasation of tumor cells in experimental models of hematogenous metastasis. Cancer Metastasis Rev 5: 77-94, 1986.
47. Evans RA: The 'seed and soil' hypothesis and the decline of radical surgery: a surgeon's opinion. Tex Med 86: 85-89, 1990.
48. Boros P and Miller CM: Hepatocyte growth factor: a multi-functional cytokine. Lancet 345: 293-295, 1995.
49. Jiang WG, Hallett MB and Puntis MC: Hepatocyte growth factor/scatter factor, liver regeneration and cancer metastasis. Br J Surg 80: 1368-1373, 1993. (Pubitemid 23345088)
50. Salerno CT, Frizelle S, Niehans GA, Ho SB, Jakkula M, Kratzke RA and Maddaus MA: Detection of occult micrometastases in non-small cell lung carcinoma by reverse transcription-polymerase chain reaction. Chest 113: 1526-1532, 1998. (Pubitemid 28307155)
51. Straub B, Muller M, Krause H, Schrader M, Goessl C, Heicappell R and Miller K: Detection of prostate-specific antigen RNA before and after radical retropubic prostatectomy and transurethral resection of the prostate using 'Light-Cycler'-based quantitative real-time polymerase chain reaction. Urology 58: 815-820, 2001.
52. Denis MG, Tessier MH, Dreno B and Lustenberger P: Circulating micrometastases following oncological surgery. Lancet 347: 913, 1996. (Pubitemid 26099575)
53. Hamdy FC and Neal DE: Haematogenous dissemination of prostate epithelial cells during surgery. Lancet 347: 325, 1996.
54. Wong IHN, Johnson PJ, Lai PBS, Lau WY and Lo YMD: Tumor-derived epigenetic changes in the plasma and serum of liver cancer patients: implications for cancer detection and monitoring. Ann NY Acad Sci 906: 102-105, 2000. (Pubitemid 30255466)
55. Liotta LA, Kleinerman J and Saidel GM: Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res 34: 997-1004, 1974.
56. Wong IHN, Lo YMD, Zhang J, et al: Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res 59: 71-73, 1999. (Pubitemid 29062959)
57. Wong IHN, Lo YMD, Yeo W, Lau WY and Johnson PJ: Frequent p15 promoter methylation in tumor and peripheral blood from hepatocellular carcinoma patients. Clin Cancer Res 6: 3516-3521, 2000.
58. Schoenfeld A, Luqmani Y, Sinnett HD, Shousha S and Coombes RC: Keratin 19 mRNA measurement to detect micrometastases in lymph nodes in breast cancer patients. Br J Cancer 74: 1639-1642, 1996. (Pubitemid 26386094)
59. Sato M, Watanabe Y, Lee T, et al: Well-differentiated hepatocellular carcinoma: clinicopathological features and results of hepatic resection. Am J Gastroenterol 90: 112-116, 1995.
60. Nagao T, Inoue S, Yoshimi F, et al: Post-operative recurrence of hepatocellular carcinoma. Ann Surg 211: 28-33, 1990.
61. Lau WY, Leung TW, Ho SK, et al: Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet 353: 797-801, 1999. (Pubitemid 29110405)
62. Takenaka K, Yoshida K, Nishizaki T, Korenaga D, Hiroshige K, Ikeda T and Sugimachi K: Post-operative prophylactic lipiodolization reduces the intrahepatic recurrence of hepatocellular carcinoma. Am J Surg 169: 400-405, 1995.
63. Trigo JM, Tabernero JM, Paz-Ares L, et al: Tumor markers at the time of recurrence in patients with germ cell tumors. Cancer 88: 162-168, 2000. (Pubitemid 30027692)